The preliminary analysis looked at the first 94 confirmed cases of COVID-19 among the study's more than 43,000 volunteers who either received two doses of the vaccine or two doses of a placebo. It found that less than 10% of infections were in participants who had received the vaccine.
More than 90% of the coronavirus cases were in people who had received the placebo.
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with...
www.pfizer.com
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.
I am trying to understand these figures.
It seems like a very low infection rate overall?
Over what time period did they measure the chances of infection? Let's say it was 60 days (27 August to 27 October)
The 14 day incidence rate in Ireland is 175/100,000 or 17/10,000
But I think it has been much higher overall in the period 27 August to 27 October. so 40 in 60 days seems very low.
Maybe the placebo is effective as well
Brendan